Rodrigues Patrícia R, Faustino Cátia, Maurício Joaquina, Carneiro Filipa
Medical Oncology, Instituto Português de Oncologia do Porto Francisco Gentil, Centro Hospitalar de Lisboa Central (EPE), Porto, PRT.
Cureus. 2024 Jun 30;16(6):e63506. doi: 10.7759/cureus.63506. eCollection 2024 Jun.
Metastatic prostate cancer treatment is based on androgen deprivation, with pharmacological or surgical castration. This treatment may be complemented with the addition of antiandrogenic drugs. In the setting of prostate-specific antigen (PSA) progression and subsequent suspension of the antiandrogenic drug, there might occur a phenomenon of antiandrogen withdrawal, leading to a decrease in PSA and/or improvement in imaging or clinical outcomes after discontinuation of the antiandrogenic agent. Although there are some descriptions of withdrawal after the cessation of enzalutamide, the physiological mechanism behind it, as well as its frequency and impact on patient survival, remain unknown. We present two clinical cases of antiandrogenic withdrawal after enzalutamide discontinuation and discuss potential contributing factors to this phenomenon.
转移性前列腺癌的治疗基于雄激素剥夺，采用药物或手术去势。这种治疗可辅以添加抗雄激素药物。在前列腺特异性抗原（PSA）进展以及随后停用抗雄激素药物的情况下，可能会出现抗雄激素撤药现象，导致停用抗雄激素药物后PSA降低和/或影像学或临床结局改善。尽管有一些关于恩杂鲁胺停药后撤药的描述，但其背后的生理机制、发生频率及其对患者生存的影响仍不清楚。我们报告两例恩杂鲁胺停药后抗雄激素撤药的临床病例，并讨论这一现象的潜在促成因素。
